IPSEN (OTCMKTS:IPSEY) Shares Gap Down - Should You Sell?

Key Points

• IPSEN (OTCMKTS:IPSEY) shares gapped down prior to trading, opening at $33.25, below the previous close of $34.29.
• The stock is currently down 3.0% and has a 50-day moving average of $32.71 and a 200-day average of $30.32.
• IPSEN operates as a biopharmaceutical company with clinical trials ongoing in several areas, including oncology and neuroscience, for treatments targeting various diseases.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $34.29, but opened at $33.25. IPSEN shares last traded at $33.25, with a volume of 100 shares.

IPSEN Stock Up 0.6%

The firm's fifty day simple moving average is $32.84 and its 200 day simple moving average is $30.38.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.